Peptide half-life modification research in Canada investigates the chemical strategies used to extend the in vivo stability and pharmacokinetic profiles of research peptides. Native peptides are often rapidly degraded by serum proteases (DPP-4, neutral endopeptidase, aminopeptidases) and cleared by renal filtration, limiting their utility as research tools. Canadian peptide chemistry and pharmacokinetics researchers study several modification strategies — PEGylation, fatty acid conjugation, D-amino acid substitution, and C-terminal amidation — to understand how each approach extends peptide half-life and affects receptor pharmacology.
PEGylation Research
PEGylation adds polyethylene glycol chains to peptides, increasing hydrodynamic radius (reducing renal clearance) and shielding the peptide from protease access. PEG-MGF (pegylated mechano growth factor) and PEGylated somatostatin analogues are studied in Canada for how PEGylation alters receptor binding kinetics and tissue distribution compared to unmodified peptides. The size and branching of PEG chains are variables in Canadian pharmacokinetics research.
Fatty Acid Conjugation Research
Fatty acid conjugation (used in semaglutide, tirzepatide, cagrilintide, liraglutide) promotes albumin binding, dramatically extending half-life from minutes to days. Canadian researchers study how C16-C18 fatty acid linker chemistry influences albumin binding affinity, receptor engagement kinetics, and tissue-specific accumulation patterns of conjugated GLP-1 and amylin analogues.
D-Amino Acid and Retro-Inverso Research
Substituting L-amino acids with D-amino acids confers protease resistance without altering receptor binding in many peptides. FOXO4-DRI is a D-amino acid retro-inverso peptide studied in Canada for its protease resistance and cell-penetrating properties. Selank and other synthetic peptides also incorporate D-amino acids for stability.
Peptide stability modification research in Canada informs the rational design of longer-acting research compounds and drug candidates across multiple therapeutic areas.
